

Stereochemistry abstracts


Latibuddin Thander, Kaushik Sarkar, Shital K. Chattopadhyay *

Tetrahedron: Asymmetry 20 (2009) 1213

$[\alpha]_D = -24$ (*c* 0.7, CHCl₃).

Source of chirality: L-Serine

Absolute configuration : (4*R*,1*S*)



C₂₀H₃₂N₂O₄

(*R*)-tert-Butyl 4-((*S*)-1-(benzylamino)-3-hydroxypropyl)-2,2-dimethyloxazolidine-3-carboxylate


Latibuddin Thander, Kaushik Sarkar, Shital K. Chattopadhyay *

Tetrahedron: Asymmetry 20 (2009) 1213

$[\alpha]_D = +9$ (*c* 1.51, MeOH)

Source of chirality: L-Serine

Absolute configuration : (2*R*,2*S*)



C₂₄H₃₀N₂O₆S

(*R*)-Benzyl 2-(tert-butoxycarbonyl)-2-((*S*)-1-tosylazetidin-2-yl)acetate


Latibuddin Thander, Kaushik Sarkar, Shital K. Chattopadhyay *

Tetrahedron: Asymmetry 20 (2009) 1213

$[\alpha]_D = -13$ (*c* 1.50, CHCl₃)

Source of chirality: L-Serine

Absolute configuration : (2*R*,2*S*)



C₂₃H₂₇N₃O₈S

(*R*)-Benzyl 2-(tert-butoxycarbonyl)-2-((*S*)-1-(4-nitrophenylsulfonyl)azetidin-2-yl)acetate


Latibuddin Thander, Kaushik Sarkar, Shital K. Chattopadhyay *

Tetrahedron: Asymmetry 20 (2009) 1213

$[\alpha]_D = -2$ (*c* 4.25, MeOH)


Source of chirality: L-Serine

Absolute configuration : (4*S*,5*S*)




C₂₈H₃₄N₂O₂Si

(4*S*,5*S*)-4-(Benzylamino)-5-((tert-butyldiphenylsilyloxy)methyl)pyrrolidin-2-one




$[\alpha]_D^{30} = -55.6$ (*c* 0.52, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3aR,5R,6S,6aR)

(S)-N-Benzyl-1-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)but-3-en-1-amine




$[\alpha]_D^{30} = -38.6$ (*c* 0.95, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3aR,5R,6S,6aR)

(S)-N-Allyl-N-benzyl-1-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)but-3-en-1-amine




$[\alpha]_D^{30} = -25.2$ (*c* 0.25, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3aR,5R,6S,6aR)

(S)-1-Benzyl-2-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)-1,2,3,6-tetrahydropyridine




$[\alpha]_D^{30} = +8.4$ (*c* 1.3, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (1R,2R,3S,9aS)

(1R,2R,3S,9aS)-Octahydro-1H-quinolizine-1,2,3-triyl triacetate




(S)-N-Benzyl-1-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)pent-4-en-1-amine

$[\alpha]_D^{30} = -30.5$ (*c* 0.85, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3aR,5R,6S,6aR)




(S)-N-allyl-N-benzyl-1-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)pent-4-en-1-amine

$[\alpha]_D^{30} = -57.6$ (*c* 4.3, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3aR,5R,6S,6aR)




(S)-1-Benzyl-2-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)-2,3,4,7-tetrahydro-1H-azepine

$[\alpha]_D^{30} = -155.6$ (*c* 0.25, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3aR,5R,6S,6aR)




(1R,2R,3S,10aS)-Decahydropyrido[1,2-a]azepine-1,2,3-triyl triacetate

$[\alpha]_D^{30} = +3.3$ (*c* 0.9, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (1R,2R,3S,10aS)




$[\alpha]_D^{30} = -15.1$ (*c* 0.62, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3aR,5R,6S,6aR)

(*R*)-N-Benzyl-1-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)prop-2-en-1-amine




$[\alpha]_D^{30} = -16.8$ (*c* 0.475, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3aR,5R,6S,6aR)

(*R*)-N-Allyl-N-benzyl-1-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)prop-2-en-1-amine




$[\alpha]_D^{30} = -9.2$ (*c* 1.2, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3aR,5R,6S,6aR)

(*R*)-1-Benzyl-2-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)-2,5-dihydro-1*H*-pyrrole




$[\alpha]_D^{30} = +38.3$ (*c* 0.36, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (6S,7R,8R,8aR)

6,7,8-Triacetyl, 1-deoxy, castanospermine




$[\alpha]_D^{30} = -34.5$ (*c* 0.575, CHCl₃)
Source of chirality: D-glucose
Absolute configuration: (3a*R*,5*R*,6*S*,6*aR*)

(*R*)-*N*-Benzyl-1-((3*aR*,5*R*,6*S*,6*aR*)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-*d*][1,3]dioxol-5-yl)pent-4-en-1-amine




Ee = 58%
 $[\alpha]_D^{22} = -59$ (*c* 1.02, CHCl₃)
Source of chirality: (-)-2,2'-methylenebis[(3*aS*,8*aR*)-3*a*,8*a*-dihydro-8*H*-indeno[1,2-*d*]oxazole]
Absolute configuration: (*R*)

1-*tert*-Butyl 2,2-diethyl 1-(5-butylfuran-2-yl)ethane-1,2,2-tricarboxylate




Ee = 72%
 $[\alpha]_D^{30} = -75$ (*c* 1.06, CHCl₃)
Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)

1-*tert*-Butyl 2,2-diethyl 1-(3,5-dimethyl-1*H*-pyrrol-2-yl)ethane-1,2,2-tricarboxylate



Ee = 29%
 $[\alpha]_D^{32} = -20$ (*c* 0.96, CHCl₃)
Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)

1-*tert*-Butyl 2,2-diethyl 1-(1*H*-pyrrol-2-yl)ethane-1,2,2-tricarboxylate




C₁₉H₂₉NO₆

1-*tert*-Butyl 2,2-diethyl 1-(1-ethyl-1*H*-pyrrol-2-yl)ethane-1,2,2-tricarboxylate

Ee = 10%

[α]_D²³ = -15 (c 1.55, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)




C₂₃H₂₉NO₆

1-*tert*-Butyl 2,2-diethyl 1-(1-phenyl-1*H*-pyrrol-2-yl)ethane-1,2,2-tricarboxylate

Ee = 10%

[α]_D²¹ = +10 (c 1.80, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)




C₂₃H₂₉NO₆

1-*tert*-Butyl 2,2-diethyl 1-(1-phenyl-1*H*-pyrrol-3-yl)ethane-1,2,2-tricarboxylate

Ee = 66%

[α]_D¹⁴ = -76 (c 0.15, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)




C₁₉H₂₉NO₆

1-*tert*-Butyl 2,2-diethyl 1-(5-ethyl-1*H*-pyrrol-2-yl)ethane-1,2,2-tricarboxylate

Ee = 45%

[α]_D²⁶ = -40 (c 0.99, CHCl₃)


Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)




Ee = 41%

$[\alpha]_D^{24} = -37$ (c 1.02, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-tert-butyl-2-oxazoline)



1-tert-Butyl 2,2-diethyl 1-(5-benzyl-1H-pyrrol-2-yl)ethane-1,2,2-tricarboxylate




Ee = 66%

$[\alpha]_D^{23} = -99$ (c 0.50, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-tert-butyl-2-oxazoline)




1-tert-Butyl 2,2-diethyl 1-(3-phenyl-1H-pyrrol-2-yl)ethane-1,2,2-tricarboxylate




Ee = 12%

$[\alpha]_D^{27} = +11$ (c 0.22, CHCl₃)

Source of chirality: (+)-2,2'-isopropylidenebis[(4R)-4-phenyl-2-oxazoline]




1-tert-Butyl 2,2-diethyl 1-(4-phenyl-1H-pyrrol-2-yl)ethane-1,2,2-tricarboxylate




Ee = 50%

$[\alpha]_D^{22} = -77$ (c 1.23, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-tert-butyl-2-oxazoline)




1-tert-Butyl 2,2-diethyl 1-[3-(4'-chlorophenyl)-1H-pyrrol-2-yl]ethane-1,2,2-tricarboxylate




1-*tert*-Butyl 2,2-diethyl 1-[4-(4'-chlorophenyl)-1*H*-pyrrol-2-yl]ethane-1,2,2-tricarboxylate

Ee = 28%
 $[\alpha]_D^{26} = -13$ (*c* 0.20, CHCl₃)
 Source of chirality: (S,S)-(−)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)




1-*tert*-Butyl 2,2-dibenzyl 1-(3,5-dimethyl-1*H*-pyrrol-2-yl)ethane-1,2,2-tricarboxylate

Ee = 38%
 $[\alpha]_D^{26} = -35$ (*c* 1.00, CHCl₃)
 Source of chirality: (S,S)-(−)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)





1,2,2-Triethyl 1-(3,5-dimethyl-1*H*-pyrrol-2-yl)ethane-1,2,2-tricarboxylate

Ee = 63%
 $[\alpha]_D^{21} = -96$ (*c* 1.24, CHCl₃)
 Source of chirality: (S,S)-(−)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)



1-(4-Bromobenzyl) 2,2-diethyl 1-(3,5-dimethyl-1*H*-pyrrol-2-yl)ethane-1,2,2-tricarboxylate

Ee = 48%
 $[\alpha]_D^{23} = -38$ (*c* 0.54, CHCl₃)
 Source of chirality: (S,S)-(−)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)





Diethyl 2-[1-(3,5-dimethyl-1H-pyrrol-2-yl)-2-oxo-2-(piperidin-1-yl)ethyl]malonate

Ee = 71%

[α]_D²⁷ = -118 (c 1.08, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-tert-butyl-2-oxazoline)





Diethyl 2-[1-(3,5-dimethyl-1H-pyrrol-2-yl)-2-oxo-2-phenylethyl]malonate

Ee = 41%

[α]_D²² = -83 (c 1.68, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-tert-butyl-2-oxazoline)




Diethyl 2-[(3,5-dimethyl-1H-pyrrol-2-yl)(phenyl)methyl]malonate

Ee = 47%

[α]_D¹⁹ = -10 (c 0.56, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-tert-butyl-2-oxazoline)




1-tert-Butyl 2,2-diethyl 1-(furan-2-yl)ethane-1,2,2-tricarboxylate

Ee = 9%

[α]_D²⁸ = -8 (c 0.31, CHCl₃)

Source of chirality: (-)-2,2'-methylenebis[(3aS,8aR)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole]




C₁₈H₂₆O₇

1-*tert*-Butyl 2,2-diethyl 1-(5-methylfuran-2-yl)ethane-1,2,2-tricarboxylate

Ee = 46%

[α]_D²⁴ = -52 (c 0.95, CHCl₃)

Source of chirality: (-)-2,2'-methylenebis[(3aS,8aR)-3a,8a-dihydro-8H-indeno[1,2-*d*]oxazole]




C₁₉H₂₈O₇

1-*tert*-Butyl 2,2-diethyl 1-(5-ethylfuran-2-yl)ethane-1,2,2-tricarboxylate

Ee = 60%

[α]_D³⁰ = -63 (c 1.07, CHCl₃)

Source of chirality: (-)-2,2'-methylenebis[(3aS,8aR)-3a,8a-dihydro-8H-indeno[1,2-*d*]oxazole]




C₂₀H₃₀O₇

1-*tert*-Butyl 2,2-diethyl 1-(5-propylfuran-2-yl)ethane-1,2,2-tricarboxylate

Ee = 57%

[α]_D²⁸ = -62 (c 1.48, CHCl₃)

Source of chirality: (-)-2,2'-methylenebis[(3aS,8aR)-3a,8a-dihydro-8H-indeno[1,2-*d*]oxazole]




C₁₉H₂₈O₇

1-*tert*-Butyl 2,2-diethyl 1-(4,5-dimethylfuran-2-yl)ethane-1,2,2-tricarboxylate

Ee = 27%

[α]_D²² = -29 (c 1.01, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)



C₁₃H₂₂O₄


(S)-2-(Hydroxymethyl)-3-(5-butylfuran-2-yl)butane-1,4-diol

Ee = 62%

[α]_D¹⁷ = -5.8 (c 1.35, CHCl₃)

Source of chirality: (-)-2,2'-methylenebis[(3a*S*,8a*R*)-3a,8a-dihydro-8*H*-indeno[1,2-*d*]oxazole]

Absolute configuration: (*S*)



C₁₃H₂₂O


(R)-2-Butyl-5-(1,2-dimethylpropyl)furan

Ee = 62%

[α]_D¹⁶ = -6.3 (c 0.66, CHCl₃)

Source of chirality: (-)-2,2'-methylenebis[(3a*S*,8a*R*)-3a,8a-dihydro-8*H*-indeno[1,2-*d*]oxazole]

Absolute configuration: (*R*)




C₁₉H₂₄O₇

Diethyl 2-(1,2,3,4-tetrahydro-6,8-dimethoxy-2-oxonaphthalen-1-yl)malonate

Ee = 48%

[α]_D³¹ = +90 (c 0.75, CHCl₃)

Source of chirality: (+)-2,2'-isopropylidenebis[(4*R*)-4-benzyl-2-oxazoline]




C₁₈H₂₂O₈

Diethyl 2-(5,7-dimethoxy-3-oxochroman-4-yl)malonate

Ee = 20%

[α]_D²⁶ = +38 (c 1.19, CHCl₃)

Source of chirality: (S,S)-(-)-2,2'-isopropylidenebis(4-*tert*-butyl-2-oxazoline)



C₃₁H₃₂O₇


Diethyl 2-(6,8-bis(benzyloxy)-1,2,3,4-tetrahydro-2-oxonaphthalen-1-yl)malonate

Ee = 56%

[α]_D³⁰ = +109 (c 0.85, CHCl₃)


Source of chirality: (+)-2,2'-isopropylidenebis[(4R)-4-benzyl-2-oxazoline]

[Φ]_D¹⁹ = -154.4 (c 0.03, CH₂Cl₂)




C₁₅H₇O₁₀CoRuSW

[Φ]_D¹⁹ = -1003.4 (c 0.05, CH₂Cl₂)








C₁₅H₇O₁₀CoRuSeW

[Φ]_D¹⁹ = -1014.7 (c 0.05, CH₂Cl₂)





C₁₅H₇O₁₀CoRuSeMo


$[\Phi]_D^{19} = +2483.0 \text{ (c 0.025, CH}_2\text{Cl}_2)$
 $\text{C}_{17}\text{H}_{12}\text{O}_9\text{NCoRuSW}$
 $[\Phi]_D^{19} = -1086.6 \text{ (c 0.05, CH}_2\text{Cl}_2)$
 $\text{C}_{17}\text{H}_{12}\text{O}_9\text{NCoRuSeW}$
 $[\Phi]_D^{19} = +282.5 \text{ (c 0.05, CH}_2\text{Cl}_2)$
 $\text{C}_{17}\text{H}_{12}\text{O}_9\text{NCoRuSeMo}$
 $[\Phi]_D^{19} = +1048.3 \text{ (c 0.05, CH}_2\text{Cl}_2)$
Absolute configuration: (R)
 $\text{C}_{15}\text{H}_{11}\text{O}_7\text{CoW}$





$[\Phi]_D^{19} = -68.2$ (*c* 0.05, CH₂Cl₂)
Absolute configuration: (S)




$[\alpha]_D^{22} = -23.7$ (*c* 0.35, MeOH)
Source of chirality: enzymatic catalysis




$[\alpha]_D^{22} = -29.6$ (*c* 0.45, MeOH)
Source of chirality: enzymatic catalysis




$[\alpha]_D^{22} = +3.1$ (*c* 0.65, MeOH): equilibrium
mixture of anomers
Source of chirality: enzymatic catalysis




(1R,2R,1'R,1''R)-*N,N'*-Di(1-phenylethyl)-1,2-cyclohexanediamine


$[\alpha]_D^{25} = -40.4$ (*c* 1.1, CHCl₃)
 Source of chirality: (*R,R*)-*trans*-1,2-diaminocyclohexane
 Absolute configuration: (1*R*,2*R*,1'*R*,1''*R*)

(1R,2R,1'R,1''R)-*N,N'*-Di[1-(4-nitrophenyl)ethyl]-1,2-cyclohexanediamine


$[\alpha]_D^{25} = -21.0$ (*c* 1, CHCl₃)
 Source of chirality: (*R,R*)-*trans*-1,2-diaminocyclohexane
 Absolute configuration: (1*R*,2*R*,1'*R*,1''*R*)

(1R,2R,1'R,1''R)-*N,N'*-Di[1-(4-chlorophenyl)ethyl]-1,2-cyclohexanediamine

$[\alpha]_D^{25} = -17.5$ (*c* 1, CHCl₃)
 Source of chirality: (*R,R*)-*trans*-1,2-diaminocyclohexane
 Absolute configuration: (1*R*,2*R*,1'*R*,1''*R*)


(1R,2R,1'R,1''R)-*N,N'*-Di(1,2,3,4-tetrahydro-1-naphthalenyl)-1,2-cyclohexanediamine

$[\alpha]_D^{25} = -115.1$ (*c* 1, CHCl₃)
 Source of chirality: (*R,R*)-*trans*-1,2-diaminocyclohexane
 Absolute configuration: (1*R*,2*R*,1'*R*,1''*R*)




(1R,2R,1'R,1''R)-N,N'-Di[1-(2-thienyl)ethyl]-1,2-cyclohexanediamine

$[\alpha]_D^{25} = -27.9$ (*c* 1, CHCl₃)
 Source of chirality: (*R,R*)-*trans*-1,2-diaminocyclohexane
 Absolute configuration: (1*R*,2*R*,1'*R*,1''*R*)




(1R,2R,1'R,1''R)-N,N'-Di[1-(2-naphthyl)ethyl]-1,2-cyclohexanediamine

$[\alpha]_D^{25} = -9.1$ (*c* 0.5, CHCl₃)
 Source of chirality: (*R,R*)-*trans*-1,2-diaminocyclohexane
 Absolute configuration: (1*R*,2*R*,1'*R*,1''*R*)





(1R,2R,1'R,1''R)-N,N'-Di[1-(4-methylphenyl)ethyl]-1,2-cyclohexanediamine

$[\alpha]_D^{25} = -29.2$ (*c* 1.2, CHCl₃)
 Source of chirality: (*R,R*)-*trans*-1,2-diaminocyclohexane
 Absolute configuration: (1*R*,2*R*,1'*R*,1''*R*)





(1R,2R,1'R,1''R)-N,N'-Di[1-(4-methoxyphenyl)ethyl]-1,2-cyclohexanediamine



$[\alpha]_D^{25} = +10.7$ (*c* 0.6, CHCl₃)
 Source of chirality: (*R,R*)-*trans*-1,2-diaminocyclohexane
 Absolute configuration: (1*R*,2*R*,1'*R*,1''*R*)

*N*-Methyl-*N*-phenyl-[{(S)-1,1'-spirobiindane-7,7'-diyl}]-phosphoramidite



Ee = 100%
 $[\alpha]_D^{25} = -25.5$ (*c* 1.0, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (S)

*N*-Ethyl-*N*-phenyl-[{(R)-1,1'-spirobiindane-7,7'-diyl}]-phosphoramidite



Ee = 100%
 $[\alpha]_D^{25} = +89.8$ (*c* 1.0, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (R)

*N,N*-Diphenyl-[{(S)-1,1'-spirobiindane-7,7'-diyl}]-phosphoramidite



Ee = 100%
 $[\alpha]_D^{25} = -171$ (*c* 1.0, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (S)

*N*-Phenyl-[{(S)-1,1'-spirobiindane-7,7'-diyl}]-phosphoramidite



Ee = 100%
 $[\alpha]_D^{17} = -103$ (*c* 0.5, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (S)

*N*-Methyl-*N*-(4-methoxyphenyl)-[(*S*)-1,1'-spirobiindane-7,7'-diyl]-phosphoramidite



Ee = 100%
 $[\alpha]_D^{25} = -20.4$ (*c* 1.0, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (*S*)

*N*-Methyl-*N*-(4-chlorophenyl)-[(*S*)-1,1'-spirobiindane-7,7'-diyl]-phosphoramidite


Ee = 100%
 $[\alpha]_D^{25} = +8.9$ (*c* 1.0, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (*S*)

*N*-Methyl-*N*-(2,6-dimethylphenyl)-[(*S*)-1,1'-spirobiindane-7,7'-diyl]-phosphoramidite

Ee = 100%
 $[\alpha]_D^{25} = -105$ (*c* 1.0, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (*S*)


(Indolin-1-yl)-[(*S*)-1,1'-spirobiindane-7,7'-diyl]-phosphoramidite

Ee = 100%
 $[\alpha]_D^{25} = -144$ (*c* 1.0, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (*S*)

 $C_{26}H_{26}NO_2P$


N-Methyl-N-phenyl-[{(R)-1,1'-spirobiindane-6,6'-dimethyl-7,7'-diyl}-phosphoramidite]

Ee = 100%
 $[\alpha]_D^{25} = +219$ (*c* 1.0, CH_2Cl_2)
 Source of chirality: resolution
 Absolute configuration: (R)

 $C_{12}H_{13}NO_2$


(+)-3-Allyl-3-hydroxy-1-methylindolin-2-one

Ee = 71%
 $[\alpha]_D^{29} = +21.4$ (*c* 1.05, CH_2Cl_2)
 Source of chirality: asymmetric synthesis
 Absolute configuration: unknown

 $C_{14}H_{15}NO_2$


(+)-1,3-Diallyl-3-hydroxyindolin-2-one

Ee = 63%
 $[\alpha]_D^{29} = +18.9$ (*c* 0.98, CH_2Cl_2)
 Source of chirality: asymmetric synthesis
 Absolute configuration: unknown

 $C_{16}H_{21}NO_2$

(+)-3-Allyl-3-hydroxy-1-neopentylindolin-2-one

Ee = 62%
 $[\alpha]_D^{29} = +37.3$ (*c* 1.35, CH_2Cl_2)
 Source of chirality: asymmetric synthesis
 Absolute configuration: unknown

 $C_{18}H_{17}NO_2$


(+) -3-Allyl-1-benzyl-3-hydroxyindolin-2-one

Ee = 56%

 $[\alpha]_D^{29} = +5.2 (c\ 1.55, \text{CH}_2\text{Cl}_2)$

Source of chirality: asymmetric synthesis

Absolute configuration: unknown

 $C_{17}H_{15}NO_2$


(+) -3-Allyl-3-hydroxy-1-phenylindolin-2-one

Ee = 62%

 $[\alpha]_D^{29} = +23.3 (c\ 1.25, \text{CH}_2\text{Cl}_2)$

Source of chirality: asymmetric synthesis

Absolute configuration: unknown

 $C_{18}H_{17}NO_4S$


(+) -3-Allyl-3-hydroxy-1-tosylindolin-2-one

Ee = 47%

 $[\alpha]_D^{29} = +5.2 (c\ 1.33, \text{CH}_2\text{Cl}_2)$

Source of chirality: asymmetric synthesis

Absolute configuration: unknown

 $C_{12}H_{12}NO_2Cl$


(+) -3-Allyl-5-chloro-3-hydroxy-1-methylindolin-2-one

Ee = 46%

 $[\alpha]_D^{29} = +2.7 (c\ 0.98, \text{CH}_2\text{Cl}_2)$

Source of chirality: asymmetric synthesis

Absolute configuration: unknown

 $C_{13}H_{15}NO_3$


(+) -3-Allyl-3-hydroxy-5-methoxy-1-methylindolin-2-one

Ee = 53%

 $[\alpha]_D^{29} = +8.0$ (*c* 1.33, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: unknown

 $C_{13}H_{15}NO_2$


(+) -3-Allyl-3-hydroxy-1,5-dimethylindolin-2-one

Ee = 54%

 $[\alpha]_D^{29} = +7.0$ (*c* 1.33, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: unknown

 $C_{12}H_{12}NO_2Cl$


(+) -3-Allyl-7-chloro-3-hydroxy-1-methylindolin-2-one

Ee = 52%

 $[\alpha]_D^{29} = +11.3$ (*c* 1.40, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: unknown

 $C_{13}H_{15}NO_2$


(+) -3-Allyl-3-hydroxy-1,7-dimethylindolin-2-one

Ee = 64%

 $[\alpha]_D^{29} = +15.8$ (*c* 1.33, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: unknown





(+) -3-Hydroxy-1-methyl-3-(2-methylallyl)indolin-2-one

Ee = 48%

 $[\alpha]_D^{29} = +15.1 (c\ 1.18, \text{CH}_2\text{Cl}_2)$

Source of chirality: asymmetric synthesis

Absolute configuration: unknown




(+) -3-Hydroxy-1-methyl-3-(2-phenylallyl)indolin-2-one

Ee = 57%

 $[\alpha]_D^{29} = +6.0 (c\ 1.55, \text{CH}_2\text{Cl}_2)$

Source of chirality: asymmetric synthesis

Absolute configuration: unknown





(+) -3-Hydroxy-3-(2-(4-methoxyphenyl)allyl)-1-methylindolin-2-one

Ee = 50%

 $[\alpha]_D^{29} = +1.1 (c\ 1.70, \text{CH}_2\text{Cl}_2)$

Source of chirality: asymmetric synthesis

Absolute configuration: unknown




(+) -3-Hydroxy-1-methyl-3-(2-(4-(trifluoromethyl)phenyl)allyl)indolin-2-one

Ee = 60%

 $[\alpha]_D^{29} = +3.0 (c\ 1.90, \text{CH}_2\text{Cl}_2)$

Source of chirality: asymmetric synthesis

Absolute configuration: unknown


 $Ee = 48\%$ $[\alpha]_D^{29} = +9.7 (c \ 1.80, \text{CH}_2\text{Cl}_2)$

Source of chirality: asymmetric synthesis

Absolute configuration: unknown



(+) -3-(2-Benzylallyl)-3-hydroxy-1-methylindolin-2-one


 $[\alpha]_D^{23} = -22.5 (c \ 1.07, \text{DMSO})$

Source of chirality: (+)-di-p-toluoyl tartaric acid

Absolute configuration: (S,S)



(S,S)-7-Amino-5-methyl-5H-dibenzo[b,d]azepin-6(7H)-one (2S,3S)-2,3-bis(4-methylbenzoyloxy)succinate hydrate


 $[\alpha]_D^{23} = -160.0 (c \ 0.96, \text{MeOH})$

Source of chirality: (+)-di-p-toluoyl tartaric acid

Absolute configuration: (S,S)




(S)-7-Amino-5-methyl-5H-dibenzo[b,d]azepin-6(7H)-one

 $[\alpha]_D^{23} = -90.6 (c \ 0.97, \text{water})$


Source of chirality: (+)-di-p-toluoyl tartaric acid

Absolute configuration: (S,S)




(S)-7-Amino-5-methyl-5H-dibenzo[b,d]azepin-6(7H)-one hydrochloride

$[\alpha]_D^{25} = -26.2$ (*c* 3.5, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (3R)

 $C_{13}H_{18}O_2$


(3R)-Ethyl-3-(4-methylphenyl)butanoate

$[\alpha]_D^{25} = +34.2$ (*c* 1.0, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (3S)

 $C_{11}H_{14}O_2$


(3S)-3-(4-Methylphenyl)butanoic acid

$[\alpha]_D^{25} = +30.1$ (*c* 1.0, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (3S)

 $C_{11}H_{16}O$


(3S)-3-(4-Methylphenyl)-1-butanol

$[\alpha]_D^{25} = +41.9$ (*c* 1.0, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (3S)

 $C_{11}H_{14}O$


(3S)-3-(4-Methylphenyl)butanal

$[\alpha]_D^{25} = +80.2$ (*c* 1.2, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (6S)




(6S)-2-Methyl-6-(4-methylphenyl)-2-hepten-4-one

$[\alpha]_D^{25} = +14.8$ (*c* 1.0, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (4R,6S)





(4R,6S)-2-Methyl-6-(4-methylphenyl)-2-hepten-4-ol

$[\alpha]_D^{22} = +7.7$ (*c* 0.57, CHCl₃)
 Source of chirality: starting material
 Absolute configuration: (S)




(+)-(S)-trans-2-(2,4-Dimethoxyphenyl)-1-(4-phenyloxazoline-2-yl)ethene

$[\alpha]_D^{21} = -38.3$ (*c* 1.44, CHCl₃)
 Source of chirality: starting material
 Absolute configuration: (S)




(-)-(S)-trans-2-(2,4-Dimethoxyphenyl)-1-(4-tert-butyloxazoline-2-yl)ethene




(+)-Bis[(S)-4-phenyloxazoline-2-yl]-2-(2-chlorophenyl)ethene

$[\alpha]_D^{20} = +50.3$ (*c* 1.89, CHCl₃)
Source of chirality: starting material
Absolute configuration: (S)




(+)-Bis[(S)-4-phenyloxazoline-2-yl]-2-(2-methoxyphenyl)ethene

$[\alpha]_D^{20} = +137.8$ (*c* 0.94, CHCl₃)
Source of chirality: starting material
Absolute configuration: (S)




L-N-isopropyl-dimethyl valinol

$[\alpha]_D = +24.3$ (*c* 5.49, EtOAc)
Absolute configuration: *S*
Source of chirality: L-valine



L-N-isopropyl-dibutyl valinol


$[\alpha]_D = +17.8$ (*c* 2.485, EtOAc)
Absolute configuration: *S*
Source of chirality: L-valine



C₁₃H₂₇NO

L-N-Cyclohexyl-dimethyl valinol


[α]_D = +28.6 (c 2.885, EtOAc)
Absolute configuration: S
Source of chirality: L-valine



C₁₉H₃₉NO

L-N-Cyclohexyl-dibutyl valinol


[α]_D = +19.3 (c 1.985, EtOAc)
Absolute configuration: S
Source of chirality: L-valine



C₁₉H₃₉NO

L-N-Cyclohexyl-diphenyl valinol


[α]_D = -42.3 (c 2.23, CH₂Cl₂)
Absolute configuration: S
Source of chirality: L-valine



C₁₇H₃₁NO


L-N-Adamantyl-dimethyl valinol

[α]_D = +26.05 (c 4.78, EtOAc)
Absolute configuration: S
Source of chirality: L-valine




C₂₃H₄₃NO
L-N-Adamantyl-dibutyl valinol

[α]_D = +22.2 (c 3.745, EtOAc)
Absolute configuration: S
Source of chirality: L-valine




C₂₇H₃₅NO
L-N-Adamantyl-diphenyl valinol

[α]_D = -34.3 (c 2.21, CH₂Cl₂)
Absolute configuration: S
Source of chirality: L-valine



C₁₄H₂₃NO
L-N-Isopropyl-dimethyl phenylalanol

[α]_D = -20.9 (c 5.705, EtOAc)
Absolute configuration: S
Source of chirality: L-phenylalanine




C₂₀H₃₅NO
L-N-Isopropyl-dibutyl phenylalanol

[α]_D = +1.1 (c 5.49, EtOAc)
Absolute configuration: S
Source of chirality: L-phenylalanine

Amanda J. Hickman, Lauren D. Hughs, Casey M. Jones, Hanhan Li, Joanne E. Redford,
Samuel J. Sobelman, J. Andrew Kouzelos, Adam. R. Johnson*


Tetrahedron: Asymmetry 20 (2009) 1279



C₂₄H₂₇NO

L-N-Isopropyl-diphenyl phenylalanol

[α]_D = +3.6 (c 5.00, EtOAc)
Absolute configuration: S
Source of chirality: L-phenylalanine




C₁₇H₂₇NO

L-N-Cyclohexyl-dimethyl phenylalanol

[α]_D = -8.6 (c 5.945, EtOAc)
Absolute configuration: S
Source of chirality: L-phenylalanine

Amanda J. Hickman, Lauren D. Hughs, Casey M. Jones, Hanhan Li, Joanne E. Redford,
Samuel J. Sobelman, J. Andrew Kouzelos, Adam. R. Johnson*

Tetrahedron: Asymmetry 20 (2009) 1279




C₂₃H₃₉NO

L-N-Cyclohexyl-dibutyl phenylalanol

[α]_D = +9.4 (c 5.205, EtOAc)
Absolute configuration: S
Source of chirality: L-phenylalanine

Amanda J. Hickman, Lauren D. Hughs, Casey M. Jones, Hanhan Li, Joanne E. Redford,
Samuel J. Sobelman, J. Andrew Kouzelos, Adam. R. Johnson*

Tetrahedron: Asymmetry 20 (2009) 1279




C₂₇H₃₁NO

L-N-Cyclohexyl-diphenyl phenylalanol

[α]_D = +5.6 (c 2.885, EtOAc)
Absolute configuration: S
Source of chirality: L-phenylalanine

Amanda J. Hickman, Lauren D. Hughs, Casey M. Jones, Hanhan Li, Joanne E. Redford,
Samuel J. Sobelman, J. Andrew Kouzelos, Adam. R. Johnson *

Tetrahedron: Asymmetry 20 (2009) 1279




C₂₁H₃₁NO
L-N-Adamantyl-dimethyl phenylalanol

[α]_D = +0.2 (c 2.435, EtOAc)
Absolute configuration: S
Source of chirality: L-phenylalanine

Amanda J. Hickman, Lauren D. Hughs, Casey M. Jones, Hanhan Li, Joanne E. Redford,
Samuel J. Sobelman, J. Andrew Kouzelos, Adam. R. Johnson *

Tetrahedron: Asymmetry 20 (2009) 1279




C₂₇H₄₃NO
L-N-Adamantyl-dibutyl phenylalanol

[α]_D = +9.9 (c 5.23, EtOAc)
Absolute configuration: S
Source of chirality: L-phenylalanine

Amanda J. Hickman, Lauren D. Hughs, Casey M. Jones, Hanhan Li, Joanne E. Redford,
Samuel J. Sobelman, J. Andrew Kouzelos, Adam. R. Johnson *

Tetrahedron: Asymmetry 20 (2009) 1279




C₃₁H₃₅NO
L-N-Adamantyl-diphenyl phenylalanol

[α]_D = +4.1 (c 4.90, EtOAc)
Absolute configuration: S
Source of chirality: L-phenylalanine


Mikio Fujii *, Sumie Yasuhara, Hiroyuki Akita *

Tetrahedron: Asymmetry 20 (2009) 1286



C₁₅H₂₀O₅
(4S,5S)-Methyl 5-hydroxy-4-(2,5-dimethoxyphenyl)hex-2(E)-enoate


Ee = 95.2%ee
[α]_D²⁹ = +4.1 (c 1.10, CHCl₃)
Source of chirality: enzymatic resolution
Absolute configuration: (4S,5S)



Ee = 98.6%ee
 $[\alpha]_D^{27} = +15.1$ (c 1.26, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (4S,5S)

C₁₅H₂₀O₅


(4S,5S)-Methyl 5-hydroxy-4-(3,4-dimethoxyphenyl)hex-2(E)-enoate



Ee = 99.8%ee
 $[\alpha]_D^{29} = +10.5$ (c 1.36, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (4S,5S)

C₁₆H₂₂O₅


(4S,5S)-Methyl 5-hydroxy-4-(2,5-dimethoxy-4-methylphenyl)hex-2(E)-enoate



Ee = 99.8%ee
 $[\alpha]_D^{21} = -5.5$ (c 2.44, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (4R,5R)

C₁₆H₂₀O₅


(4S,5S)-Methyl 5-acetoxy-4-(4-methoxyphenyl)hex-2(E)-enoate



Ee = 98.5%ee
 $[\alpha]_D^{23} = +1.8$ (c 1.12, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (4R,5R)

C₁₇H₂₂O₅


(4S,5S)-Methyl 5-acetoxy-4-(2-methoxy-4-methylphenyl)hex-2(E)-enoate



Ee = >99.9%ee
 $[\alpha]_D^{23} = +21.2$ (c 2.07, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (4S,5S)

C₁₄H₁₈O₄


(4S,5S)-Methyl 5-hydroxy-4-(4-methoxyphenyl)hex-2(E)-enoate



Ee = >99%ee
 $[\alpha]_D^{23} = +2.0$ (c 1.10, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (4S,5S)

C₁₅H₂₀O₄


(4S,5S)-Methyl 5-hydroxy-4-(2-methoxy-4-methylphenyl)hex-2(E)-enoate



Ee = >99%ee
 $[\alpha]_D^{29} = -14.2$ (c 1.00, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (4S,5S)

C₁₅H₂₀O₄


(4S,5S)-Methyl 5-hydroxy-4-(4-methoxy-2-methylphenyl)hex-2(E)-enoate



Ee = 99.3%ee
 $[\alpha]_D^{27} = +17.6$ (c 1.01, CHCl₃)
 Source of chirality: enzymatic resolution
 Absolute configuration: (4S,5S)


C₁₅H₂₀O₄

(4S,5S)-Methyl 5-hydroxy-4-(2-methoxy-5-methylphenyl)hex-2(E)-enoate

 $Ee = 98.2\%ee$ $[\alpha]_D^{27} = -1.7 (c \ 1.01, \ CHCl_3)$


Source of chirality: enzymatic resolution

Absolute configuration: (4S,5S)

 $C_{15}H_{20}O_4$ (4S,5S)-Methyl 5-hydroxy-4-(3-methoxy-4-methylphenyl)hex-2(*E*)-enoate $Ee = 99.8\%ee$ $[\alpha]_D^{29} = +18.6 (c \ 1.11, \ CHCl_3)$


Source of chirality: enzymatic resolution

Absolute configuration: (4R,5R)

 $C_{17}H_{22}O_3$ (4S,5S)-Methyl 5-acetoxy-4-(4-methoxy-2-methylphenyl)hex-2(*E*)-enoate $Ee = 98.2\%ee$ $[\alpha]_D^{27} = -10.0 (c \ 1.01, \ CHCl_3)$

Source of chirality: enzymatic resolution


Absolute configuration: (4R,5R)

 $C_{17}H_{22}O_5$ (4S,5S)-Methyl 5-acetoxy-4-(2-methoxy-5-methylphenyl)hex-2(*E*)-enoate $Ee = 99.8\%ee$ $[\alpha]_D^{23} = +12.5 (c \ 1.07, \ CHCl_3)$

Source of chirality: enzymatic resolution

Absolute configuration: (4R,5R)

 $C_{17}H_{22}O_5$ (4S,5S)-Methyl 5-acetoxy-4-(3-methoxy-4-methylphenyl)hex-2(*E*)-enoate

 $C_{17}H_{22}O_6$


(4S,5S)-Methyl 5-acetoxy-4-(2,5-dimethoxyphenyl)hex-2(E)-enoate

Ee = 98.2%ee

 $[\alpha]_D^{25} = +6.5$ (*c* 1.03, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: (4R,5R)

 $C_{17}H_{22}O_6$


(4S,5S)-Methyl 5-acetoxy-4-(3,4-dimethoxyphenyl)hex-2(E)-enoate

Ee = 98.0%ee

 $[\alpha]_D^{27} = +11.2$ (*c* 1.07, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: (4R,5R)

 $C_{18}H_{24}O_6$


(4S,5S)-Methyl 5-acetoxy-4-(2,5-dimethoxy-4-methylphenyl)hex-2(E)-enoate

Ee = 99.8%ee

 $[\alpha]_D^{14} = +5.6$ (*c* 0.36, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: (4R,5R)

 $C_{14}H_{18}O_4$


(4S,5S)-Methyl 4-hydroxy-5-(4-methoxyphenyl)hex-2(E)-enoate

Ee = >99%ee

 $[\alpha]_D^{23} = -12.9$ (*c* 1.01, CHCl₃)

Source of chirality: stereoselective rearrangement

Absolute configuration: (4S,5S)




Ee = >99%ee

 $[\alpha]_D^{20} = -11.7$ (*c* 1.40, CHCl₃)

Source of chirality: stereoselective rearrangement

Absolute configuration: (4S,5S)


C₁₅H₂₀O₄(4S,5S)-Methyl 4-hydroxy-5-(4-methoxy-2-methylphenyl)hex-2(*E*)-enoate

Ee = >99%ee

 $[\alpha]_D^{20} = +25.1$ (*c* 0.53, CHCl₃)

Source of chirality: stereoselective rearrangement

Absolute configuration: (4S,5S)


C₁₅H₂₀O₄(4S,5S)-Methyl 4-hydroxy-5-(2-methoxy-4-methylphenyl)hex-2(*E*)-enoate

Ee = 99.3%ee

 $[\alpha]_D^{21} = -8.4$ (*c* 1.00, CHCl₃)

Source of chirality: stereoselective rearrangement

Absolute configuration: (4S,5S)

C₁₅H₂₀O₄(4S,5S)-Methyl 4-hydroxy-5-(4-methoxy-3-methylphenyl)hex-2(*E*)-enoate


Ee = 98.2%ee

 $[\alpha]_D^{21} = 0$ (*c* 0.78, CHCl₃)

Source of chirality: stereoselective rearrangement

Absolute configuration: (4S,5S)

C₁₅H₂₀O₄(4S,5S)-Methyl 4-hydroxy-5-(2,5-dimethoxyphenyl)hex-2(*E*)-enoate


 $C_{15}H_{20}O_5$ (4S,5S)-Methyl 4-hydroxy-5-(3,4-dimethoxyphenyl)hex-2(*E*)-enoate

Ee = 95.2%ee

 $[\alpha]_D^{21} = -4.1$ (*c* 0.60, CHCl₃)

Source of chirality: stereoselective rearrangement

Absolute configuration: (4S,5S)


 $C_{15}H_{20}O_5$ (4S,5S)-Methyl 4-hydroxy-5-(2,5-dimethoxyphenyl)hex-2(*E*)-enoate

Ee = 98.6%ee

 $[\alpha]_D^{23} = -12.1$ (*c* 1.21, CHCl₃)

Source of chirality: stereoselective rearrangement

Absolute configuration: (4S,5S)


 $C_{16}H_{22}O_5$ (4S,5S)-Methyl 4-hydroxy-5-(2,5-dimethoxy-4-methylphenyl)hex-2(*E*)-enoate

Ee = 99.8%ee

 $[\alpha]_D^{23} = -5.8$ (*c* 1.22, CHCl₃)

Source of chirality: stereoselective rearrangement

Absolute configuration: (4S,5S)

 C_8H_8O


(R)-(+)-Phenyloxirane

Ee = 46%

 $[\alpha]_D^{22} = +21.5$ (*c* 0.8, PhH)


Source of chirality: chiral catalyst

Absolute configuration: (R)

 $C_8H_8O_2$


(R)-(+)-4-Hydroxyphenyloxirane

Ee = 57%
 $[\alpha]_D^{25} = +4.95$ (*c* 0.8, CHCl₃)
 Source of chirality: chiral catalyst
 Absolute configuration: (R)

 C_8H_7OCl


(R)-(-)-(4-Chlorophenyl) oxirane

Ee = 46%
 $[\alpha]_D^{22} = -11.5$ (*c* 0.65, CHCl₃)
 Source of chirality: chiral catalyst
 Absolute configuration: (R)

 $C_8H_7NO_3$


(R)-(-)-(3-Nitrophenyl) oxirane

Ee = 63%
 $[\alpha]_D^{20} = -1.6$ (*c* 2.1, CHCl₃)
 Source of chirality: chiral catalyst
 Absolute configuration: (R)


 $C_8H_7NO_3$

(R)-(-)-(2-Nitrophenyl) oxirane


Ee = 68%
 $[\alpha]_D^{19.5} = -72.9$ (*c* 1.20, CHCl₃)
 Source of chirality: chiral catalyst
 Absolute configuration: (R)




Ee = 35%
 $[\alpha]_D^{25} = +19.3$ (*c* 0.05, CHCl₃)
 Source of chirality: chiral catalyst
 Absolute configuration: (2*R*,3*R*)




Ee = 71%
 $[\alpha]_D^{25} = +4.3$ (*c* 0.03, CHCl₃)
 Source of chirality: chiral catalyst
 Absolute configuration: (2*R*,3*R*)



$[\alpha]_D^{20} = -60.3$ (*c* 1.0, DMSO)
 Absolute configuration: (3*S*,5*A*,8*S*)




$[\alpha]_D^{20} = +22.6$ (*c* 1.0, DMSO)
 Absolute configuration: (3*S*,5*A*,8*S*)



$[\alpha]_D^{20} = +60.1$ (*c* 1.0, DMSO)
Absolute configuration: (3*R*,5*A*,8*R*)




(3*R*,5*A*,8*R*)-3,8-Di(propan-2-yl)-1,6-dioxa-4,9-diaza-5*λ*⁵-phosphaspiro[4.4]-nonane-2,7-dione




$[\alpha]_D^{20} = -22.6$ (*c* 1.0, DMSO)
Absolute configuration: (3*R*,5*A*,8*R*)




(3*R*,5*A*,8*R*)-3,8-Di(propan-2-yl)-1,6-dioxa-4,9-diaza-5*λ*⁵-phosphaspiro[4.4]-nonane-2,7-dione




$[\alpha]_D^{20} = -55.7$ (*c* 1.0, acetone)
Absolute configuration: (3*S*,5*A*,8*S*)




(3*S*,5*A*,8*S*)-3,8-Bis(2-methylpropyl)-1,6-dioxa-4,9-diaza-5*λ*⁵-phosphaspiro[4.4]-nonane-2,7-dione



$[\alpha]_D^{20} = +31.7$ (*c* 1.0, acetone)
Absolute configuration: (3*S*,5*A*,8*S*)




(3*S*,5*A*,8*S*)-3,8-Bis(2-methylpropyl)-1,6-dioxa-4,9-diaza-5*λ*⁵-phosphaspiro[4.4]-nonane-2,7-dione




$[\alpha]_D^{20} = +55.4$ (*c* 1.0, acetone)
Absolute configuration: (3*R*,5*A*,8*R*)

$C_{12}H_{23}N_2O_4P$
(3*R*,5*A*,8*R*)-3,8-Bis(2-methylpropyl)-1,6-dioxa-4,9-diaza-5*lambda*⁵-phosphaspiro[4.4]-nonane-2,7-dione




$[\alpha]_D^{20} = -31.9$ (*c* 1.0, acetone)
Absolute configuration: (3*R*,5*A*,8*R*)

$C_{12}H_{23}N_2O_4P$
(3*R*,5*A*,8*R*)-3,8-Bis(2-methylpropyl)-1,6-dioxa-4,9-diaza-5*lambda*⁵-phosphaspiro[4.4]-nonane-2,7-dione




Ee = 78% (HPLC)
 $[\alpha]_D^{20} = +26.0$ (*c* 1.1, CHCl₃)
Source of chirality: organocatalytic kinetic resolution
Absolute configuration: (p*R*)

$C_{15}H_{12}FeN_2O$
(*pR*)-2-(2'-Pyrimidyl)ferrocenecarbaldehyde



Ee = 56% (HPLC)
 $[\alpha]_D^{20} = +648$ (*c* 0.05, CHCl₃)
Source of chirality: organocatalytic kinetic resolution
Absolute configuration: (p*S*,*E*)

$C_{18}H_{16}FeN_2O$
(*pS,E*)-4-[2-(2'-Pyrimidyl)ferrocenyl]but-3-ene-2-one




(R,pS)-4-[2-(2'-Pyrimidyl)ferrocenyl]-4-hydroxy-2-butanone

Ee = 52% (HPLC)

 $[\alpha]_D^{20} = -28.0$ (*c* 0.05, CHCl₃)

Source of chirality: organocatalytic kinetic resolution

Absolute configuration: (R,pS)





(2R,6S)-2-Hydroxy-alpha-cyclogeraniol

Ee = 99%

 $[\alpha]_D^{20} = +57.8$ (*c* 2, CH₂Cl₂)

Source of chirality: lipase-mediated resolution

Absolute configuration: (2R,6S)





(2R,6S)-2-Hydroxy-alpha-cyclogeraniol acetate

Ee = 37%

 $[\alpha]_D^{20} = +26.1$ (*c* 2, CHCl₃)

Source of chirality: lipase-mediated resolution

Absolute configuration: (2R,6S)




(2R,6S)-2-Acetoxy-alpha-cyclogeraniol acetate

Ee = 96%

 $[\alpha]_D^{20} = +8.5$ (*c* 2.5, CHCl₃)

Source of chirality: lipase-mediated resolution


Absolute configuration: (2R,6S)

 $C_{10}H_{18}O_2$ (2R,6S)-2-Hydroxy- γ -cyclogeraniol

Ee = 99%

 $[\alpha]_D^{20} = 47.2$ (*c* 2, CHCl₃)


Source of chirality: lipase-mediated resolution

Absolute configuration: (2*R*,6*S*) $C_{12}H_{20}O_3$ (2*S*,6*R*)-2-Hydroxy- γ -cyclogeraniol acetate

Ee = 32%

 $[\alpha]_D^{20} = +2.5$ (*c* 2, CHCl₃)


Source of chirality: lipase-mediated resolution

Absolute configuration: (2*S*,6*R*) $C_{12}H_{20}O_3$ (2*R*,6*S*)-2-Acetoxy- γ -cyclogeraniol

Ee = 89%

 $[\alpha]_D^{20} = 52.5$ (*c* 2, CHCl₃)

Source of chirality: lipase-mediated resolution



Absolute configuration: (2*R*,6*S*) $C_{14}H_{22}O_4$ (2*R*,6*S*)-2-Acetoxy- γ -cyclogeraniol acetate

Ee = 99%

 $[\alpha]_D^{20} = 20.1$ (*c* 1, CHCl₃)

Source of chirality: lipase-mediated resolution

Absolute configuration: (2*R*,6*S*)



(2R)-2-Hydroxy- β -cyclogeraniol

Ee = 99%

 $[\alpha]_D^{20} = +23.8$ (*c* 1, CHCl₃)

Source of chirality: lipase-mediated resolution

Absolute configuration: (2R)


(2S)-2-Hydroxy- β -cyclogeraniol acetate

Ee = 30%

 $[\alpha]_D^{20} = 8.9$ (*c* 2, CHCl₃)

Source of chirality: lipase-mediated resolution

Absolute configuration: (2S)



(2R)-2-Acetoxy- β -cyclogeraniol acetate

Ee = 99%

 $[\alpha]_D^{20} = 2.9$ (*c* 2.5, CHCl₃)

Source of chirality: lipase-mediated resolution

Absolute configuration: (2R)


(3R,6S)-3-Hydroxy- α -cyclogeraniol

Ee = 99%

 $[\alpha]_D^{20} = 76.1$ (*c* 2, CHCl₃)

Source of chirality: lipase-mediated resolution


Absolute configuration: (3R,6S)

 $C_{12}H_{20}O_3$ (3R,6S)-3-Acetoxy- α -cyclogeraniol

Ee = 7%

 $[\alpha]_D^{20} = 8$ (*c* 2, CHCl₃)


Source of chirality: lipase-mediated resolution

Absolute configuration: (3*R*,6*S*) $C_{12}H_{20}O_3$ (3*S*,6*R*)-3-Hydroxy- α -cyclogeraniol acetate

Ee = 52%

 $[\alpha]_D^{20} = +49.6$ (*c* 2, CHCl₃)


Source of chirality: lipase-mediated resolution

Absolute configuration: (3*S*,6*R*) $C_{14}H_{22}O_4$ (3*S*,6*R*)-3-Acetoxy- α -cyclogeraniol acetate

Ee = 94%

 $[\alpha]_D^{20} = +17.9$ (*c* 2, CHCl₃)

Source of chirality: lipase-mediated resolution


Absolute configuration: (3*S*,6*R*) $C_{12}H_{20}O_3$ (3*S*)-3-Hydroxy- β -cyclogeraniol acetate

Ee = 10%

 $[\alpha]_D^{20} = +15.6$ (*c* 0.5, CHCl₃)

Source of chirality: lipase-mediated resolution


Absolute configuration: (3*S*)

 $C_{14}H_{22}O_4$ (3R)-3-Acetoxy- β -cyclogeraniol acetate

Ee = 27%

 $[\alpha]_D^{20} = 20.8$ (*c* 1, MeOH)


Source of chirality: lipase-mediated resolution

Absolute configuration: (3*R*) $C_{10}H_{18}O_2$ (4*S*,6*R*)-4-Hydroxy- γ -cyclogeraniol

Ee = 99%

 $[\alpha]_D^{20} = +29.7$ (*c* 2, CHCl₃)


Source of chirality: lipase-mediated resolution

Absolute configuration: (4*S*,6*R*) $C_{12}H_{20}O_3$ (4*R*,6*S*)-4-Acetoxy- γ -cyclogeraniol

Ee = 76%

 $[\alpha]_D^{20} = 4.9$ (*c* 2, CHCl₃)

Source of chirality: lipase-mediated resolution


Absolute configuration: (4*R*,6*S*) $C_{12}H_{20}O_3$ (4*S*,6*R*)-4-Hydroxy- γ -cyclogeraniol acetate

Ee = 90%

 $[\alpha]_D^{20} = +28.1$ (*c* 2, CHCl₃)

Source of chirality: lipase-mediated resolution


Absolute configuration: (4*S*,6*R*)

 $C_{14}H_{22}O_4$ (4R,6S)-4-Acetoxy- γ -cyclogeraniol acetate

Ee = 92%

 $[\alpha]_D^{20} = 16.7$ (*c* 2, CHCl₃)


Source of chirality: lipase-mediated resolution

Absolute configuration: (4*R*,6*S*) $C_{14}H_{22}O_4$ (4*R*)-4-Acetoxy- β -cyclogeraniol acetate

Ee = 76%

 $[\alpha]_D^{20} = +62.4$ (*c* 2, CHCl₃)


Source of chirality: lipase-mediated resolution

Absolute configuration: (4*R*) $C_{10}H_{16}O$ (1*S*,5*R*)-8,8-Dimethyl-2-methylene-6-oxabicyclo[3.2.1]octane

Ee = 99%

 $[\alpha]_D^{20} = 79.9$ (*c* 0.6, CH₂Cl₂)

Source of chirality: lipase-mediated resolution


Absolute configuration: (1*S*,5*R*) $C_{10}H_{14}O_2$ (1*S*,5*R*)-8,8-Dimethyl-2-methylene-6-oxabicyclo[3.2.1]octan-7-one

Ee = 99%

 $[\alpha]_D^{20} = 288.1$ (*c* 1, CHCl₃)

Source of chirality: lipase-mediated resolution

Absolute configuration: (1*S*,5*R*)


 $C_{10}H_{16}O_2$ (6S)-3-Keto- α -cyclogeraniol

Ee = 99%

 $[\alpha]_D^{20} = -99.1$ (*c* 1, MeOH)

Source of chirality: lipase-mediated resolution

Absolute configuration: (6S)


 $C_{10}H_{18}O$ (6R)- γ -Cyclogeraniol

Ee = 99%

 $[\alpha]_D^{20} = 21.3$ (*c* 2, CHCl₃)


Source of chirality: lipase-mediated resolution

Absolute configuration: (6R)

 $C_{11}H_{22}O_3Si$ (3S)-3-[(1-(*tert*-Butyl)-1,1-dimethylsilyl)oxy]-4-pentenoic acid $[\alpha]_D^{25} = +1.2$ (*c* 1.2, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3S)


 $[\alpha]_D^{25} = +9.0$ (*c* 1.25, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (2R)


 $C_{12}H_{18}O_2$

(2R)-5-(Benzylxy)pentan-2-ol




$[\alpha]_D^{25} = +19.6$ (*c* 0.65, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (3*R*)

C₁₀H₂₀O₃
(4*R*)-4-(Tetrahydro-2*H*-2-pyranyloxy)pentan-1-ol




$[\alpha]_D^{25} = +5.6$ (*c* 1.45, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (E,6*R*)

C₁₄H₂₄O₄
Ethyl (E,6*R*)-6-(tetrahydro-2*H*-2-pyranyloxy)-2-heptenoate




$[\alpha]_D^{25} = -1.4$ (*c* 1.25, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (E,6*R*)

C₁₂H₂₂O₃
(*E,6R*)-6-(Tetrahydro-2*H*-2-pyranyloxy)-2-hepten-1-ol




$[\alpha]_D^{25} = +15.1$ (*c* 1.15, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (2*R*,3*R*) (3*R*)


C₁₂H₂₂O₄
{(2*R*,3*R*)-3-[{(3*R*)-3-(Tetrahydro-2*H*-2-pyranyloxy)butyl]oxirane-2-yl)methanol}

 $C_{18}H_{36}O_3Si$ *tert*-Butyl(dimethyl){(1*R*)-1-[(3*R*)-3-(tetrahydro-2*H*-2-pyranloxy)butyl]-2-propenyl}oxy)silane


$[\alpha]_D^{25} = -0.8$ (*c* 0.75, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (1*R*) (3*R*)

 $C_{13}H_{28}O_2Si$ (2*R*,5*R*)-5-{{[1-(*tert*-Butyl)-1,1-dimethylsilyl]oxy}-6-hepten-2-ol


$[\alpha]_D^{25} = -0.8$ (*c* 0.7, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (2*R*,5*R*)

 $C_{24}H_{48}O_4Si_2$ *tert*-Butyl[((1*R*,4*R*,8*S*)-8-{{[1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}-4-methyl-6-methylene-1-vinyl-9-decenyl}oxy]dimethylsilane

$[\alpha]_D^{25} = -7.7$ (*c* 0.4, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (1*R*,4*R*,8*S*)


 $C_{12}H_{20}O_4$ (3*S*,7*R*,10*R*)-3,10-Dihydroxy-7-methyl-1,11-dodecadiene-5-one

$[\alpha]_D^{25} = -6.6$ (*c* 0.75, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (3*S*,7*R*,10*R*)




(4S,7R,10R)-4,7-Dihydroxy-10-methyl-3,4,7,8,9,10-hexahydro-2H-2-oxecinone

$[\alpha]_D^{25} = -29.2$ (*c* 0.5, MeOH)
Source of chirality: asymmetric synthesis
Absolute configuration: (4S,7R,10R)




$C_{11}H_{20}O_4$
(2R,3R)-3-[3-(Tetrahydro-2H-2-pyranyloxy)propyl]oxiran-2-yl)methanol

$[\alpha]_D^{25} = +17.5$ (*c* 2.95, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (2R,3R)




$C_{11}H_{19}O_3I$
2-{3-[(2R,3S)-3-(Iodomethyl)oxiran-2-yl]propoxy}tetrahydro-2H-2-pyran

$[\alpha]_D^{25} = -3.8$ (*c* 2.4, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (2R,3S)




$C_{11}H_{20}O_3$
(3R)-6-(Tetrahydro-2H-2-pyranyloxy)-1-hexen-3-ol


$[\alpha]_D^{25} = -9.1$ (*c* 0.45, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (2R)




$[\alpha]_D^{25} = -7.1$ (*c* 1.95, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (1*R*)




tert-Butyl(dimethyl)[(1*R*)-1-[3-(tetrahydro-2*H*-2-pyranoyloxy)propyl]-2-propenyl]oxy]silane



$[\alpha]_D^{25} = -5.3$ (*c* 2.55, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (4*R*)




(4*R*)-4-[[1-(*tert*-Butyl)-1,1-dimethylsilyl]oxy]-5-hexen-1-ol




$[\alpha]_D^{25} = -2.8$ (*c* 0.7, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (1*R*,8*S*)



tert-Butyl[((1*R*,8*S*)-8-[[1-(*tert*-butyl)-1,1-dimethylsilyl]oxy]-6-methylene-1-vinyl-9-decenyloxy]dimethylsilane



$[\alpha]_D^{25} = -3.8$ (*c* 0.55, CHCl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (4*R*) (3*S*)



(4*R*)-4-Hydroxy-5-hexenyl(3*S*)-3-hydroxy-4-pentenoate